Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human sera

Roques, Pierre; Fritzer, Andrea; Bosquet, Nathalie; Wressnigg, Nina; Hochreiter, Romana; Bossevot, Laetitia; Pascal, Quentin; Guéhenneux, Fabienne; Bitzer, Annegret; Ramljak, Irena Corbic; Grand, Roger Le; Lundberg, Urban; Meinke, Andreas

doi:10.1172/jci.insight.160173

Cited by 28 publications

(22 citation statements)

References 47 publications

(69 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…132,200). A three-dose phase I trial of VLA1553 found that low and medium vaccine doses were well tolerated and immunogenic; encouragingly, there was no discernible immune response following the third dose, suggesting that vaccinated participants were protected against, essentially, a repeat viral challenge (for example, had sterilizing immunity) 201,202 . Follow-up studies in mice and non-human primates demonstrated that passive transfer of serum samples from the VLA1553 phase I study led to protection against CHIKV challenge 200 .…”

Section: Vaccine-based Prevention Of Chikungunya Fevermentioning

confidence: 99%

“…In 2022, the results of a USA-based randomized controlled trial of VLA1553 showed that nearly 100% of participants, including persons aged 65 or older, had met the proposed threshold for seroprotection after a single dose, and the vaccine was deemed safe and well tolerated 202 . Follow-up on a subgroup of participants will continue for 5 years and an additional trial in adolescents is under way in Brazil, with the hope that it may be one of the first countries in an endemic area to provide approval.…”

Section: Vaccine-based Prevention Of Chikungunya Fevermentioning

confidence: 99%

See 1 more Smart Citation

Chikungunya fever

Bartholomeeusen

Daniel²,

LaBeaud

et al. 2023

Nat Rev Dis Primers

View full text Add to dashboard Cite

Chikungunya virus is widespread throughout the tropics, where it causes recurrent outbreaks of chikungunya fever. In recent years, outbreaks have afflicted populations in East and Central Africa, South America and Southeast Asia. The virus is transmitted by Aedes aegypti and Aedes albopictus mosquitoes. Chikungunya fever is characterized by severe arthralgia and myalgia that can persist for years and have considerable detrimental effects on health, quality of life and economic productivity. The effects of climate change as well as increased globalization of commerce and travel have led to growth of the habitat of Aedes mosquitoes. As a result, increasing numbers of people will be at risk of chikungunya fever in the coming years. In the absence of specific antiviral treatments and with vaccines still in development, surveillance and vector control are essential to suppress re-emergence Nature Reviews Disease Primers | (2023) 9:17 2 0123456789();: PrimerWith the increasing global distribution of the Aedes mosquitoes and their ability to adapt to urban settings, the urban transmission cycle is increasingly important. Here, during a blood meal on an infected person, the female mosquito ingests the virus, which infects various mosquito tissues, including the salivary glands. During a subsequent blood meal by the infected mosquito, the virus is deposited in the skin of an uninfected person along with mosquito saliva, infecting the person and perpetuating the viral replication cycle 14 . Phylogenetic analysis identified three distinct lineages corresponding to their respective geographical origin: West African, East Central South African (ECSA) and Asian lineage 15,16 . The ECSA lineage is further divided into two clades: ECSA1, which consists entirely of ancestral CHIKV sequences, and ECSA2, which contains sequences from the Central African Republic, Cameroon, Gabon and the Republic of Congo 17,18 . Since its discovery in 1952, CHIKV has been reported to be circulating and causing sporadic outbreaks in sub-Saharan Africa. In 2004, an ECSA CHIKV strain emerged in Kenya and subsequently spread to the Indian Ocean Islands, where it caused outbreaks of an unprecedented magnitude, particularly in La Réunion [19][20][21][22][23][24] . The extent of this outbreak has led to the emergence of a fourth phylogenetic lineage termed Indian Ocean lineage, which has subsequently dispersed to Asia and India 25 and caused autochthonous transmission (local disease spread) in Mediterranean Europe (Italy and France) 26,27 .In December 2013, another major outbreak occurred when a strain from the Asian lineage emerged for the first time on the Caribbean Saint Martin Island, from where the virus spread to more than 50 countries of the South American continent, causing a conservatively estimated 1 million infections 28,29 . In 2014, the ECSA lineage was reported in Northeast Brazil, where it continues to circulate as the most prevalent strain today 30 .Most of the Indian Ocean lineage is characterized by an adaptive mutation in the E1 glycopr...

show abstract

Section: Vaccine-based Prevention Of Chikungunya Fevermentioning

confidence: 99%

Section: Vaccine-based Prevention Of Chikungunya Fevermentioning

confidence: 99%

Chikungunya fever

Bartholomeeusen

Daniel²,

LaBeaud

et al. 2023

Nat Rev Dis Primers

View full text Add to dashboard Cite

show abstract

“…VLA1553 was first investigated as part of a collaborative European research consortium (ICRES FP7-HEALTH project; https://cordis.europa.eu/project/id/261202). The vaccine is a monovalent, single-dose, live-attenuated vaccine for humans that received Fast Track designation from the FDA in December 2018 [44, 45].…”

Section: Methodsmentioning

confidence: 99%

Immunogenicity, safety and duration of protection afforded by chikungunya virus vaccines undergoing human clinical trials

Rao,

Erku,

Mahalingam

et al. 2024

Journal of General Virology

View full text Add to dashboard Cite

Background. Chikungunya virus (CHIKV) causes chikungunya fever and has been responsible for major global epidemics of arthritic disease over the past two decades. Multiple CHIKV vaccine candidates are currently undergoing or have undergone human clinical trials, with one vaccine candidate receiving FDA approval. This scoping review was performed to evaluate the ‘efficacy’, ‘safety’ and ‘duration of protection’ provided by CHIKV vaccine candidates in human clinical trials. Methods. This scoping literature review addresses studies involving CHIKV vaccine clinical trials using available literature on the PubMed, Medline Embase, Cochrane Library and Clinicaltrial.gov databases published up to 25 August 2023. Covidence software was used to structure information and review the studies included in this article. Results. A total of 1138 studies were screened and, after removal of duplicate studies, 12 relevant studies were thoroughly reviewed to gather information. This review summarizs that all seven CHIKV vaccine candidates achieved over 90 % seroprotection against CHIKV after one or two doses. All vaccines were able to provide neutralizing antibody protection for at least 28 days. Conclusions. A variety of vaccine technologies have been used to develop CHIKV vaccine candidates. With one vaccine candidate having recently received FDA approval, it is likely that further CHIKV vaccines will be available commercially in the near future.

show abstract

“…67,68 The ∆5nsP3 virus showed a very good safety profile and efficacy in mice and cynomolgus macaques 69 and has undergone clinical testing by Valneva. 70 The company recently successfully completed a Phase III trial (NCT04546724) (Table 1). The trial analysis showed that 98.9% of participants achieved protective levels of CHIKV-neutralizing antibodies one month after receiving a single vaccination, and 96.3% of participants had protective CHIKVneutralizing antibody titers six months after receiving a single vaccination (Valneva, press release).…”

Section: Live-attenuated Virusesmentioning

confidence: 99%

Chikungunya Vaccine Candidates: Current Landscape and Future Prospects

Schmidt¹,

Schnierle²

2022

DDDT

View full text Add to dashboard Cite

Chikungunya virus (CHIKV) is an alphavirus that has spread globally in the last twenty years. Although mortality is rather low, infection can result in debilitating arthralgia that can persist for years. Unfortunately, no treatments or preventive vaccines are currently licensed against CHIKV infections. However, a large range of promising preclinical and clinical vaccine candidates have been developed during recent years. This review will give an introduction into the biology of CHIKV and the immune responses that are induced by infection, and will summarize CHIKV vaccine development.

show abstract

Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human sera

Cited by 28 publications

References 47 publications

Chikungunya fever

Chikungunya fever

Immunogenicity, safety and duration of protection afforded by chikungunya virus vaccines undergoing human clinical trials

Chikungunya Vaccine Candidates: Current Landscape and Future Prospects

Contact Info

Product

Resources

About